Category: Europe

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
September 4, 2019 Off

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union

By BusinessWire

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Schreiner MediPharm and Applied DNA Sciences Offer Forensic Counterfeit-Proof Feature for Pharma Labels
August 13, 2019 Off

Schreiner MediPharm and Applied DNA Sciences Offer Forensic Counterfeit-Proof Feature for Pharma Labels

By Dino Mustafić

A new forensic authentication feature for pharmaceutical labels is offered by Schreiner MediPharm in cooperation with Applied DNA Sciences: SigNature® DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect their products against counterfeiting and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.

Novo Nordisks operating profit up 12% in Danish kroner, half year
August 9, 2019 Off

Novo Nordisks operating profit up 12% in Danish kroner, half year

By Dino Mustafić

Novo Nordisk’s operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019 with reported sales within Diabetes and obesity increased by 10% to DKK 50.1 billion (6% at CER), driven by Diabetes growing 4% at CER and Obesity growing 56% at CER. Sales within Biopharmaceuticals increased by 7% to DKK 9.3 billion (3% at CER).